Eintrag weiter verarbeiten
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid
Gespeichert in:
| Zeitschriftentitel: | CNS Neuroscience & Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | CNS Neuroscience & Therapeutics, 25, 2019, 5, S. 632-637 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio |
|---|---|
| author |
Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio |
| spellingShingle |
Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio CNS Neuroscience & Therapeutics Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid Pharmacology (medical) Physiology (medical) Psychiatry and Mental health Pharmacology |
| author_sort |
liguori, claudio |
| spelling |
Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio 1755-5930 1755-5949 Wiley Pharmacology (medical) Physiology (medical) Psychiatry and Mental health Pharmacology http://dx.doi.org/10.1111/cns.13098 <jats:title>Summary</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiatric manifestation in patients affected by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores obtained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order to measure irritability as a consequence of these treatments.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected data from 17 patients treated by PER, 16 patients treated by LEV, and 16 patients under VPA treatment followed for 12 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We did not document significant changes of I‐EPI questionnaire between baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI among PER, LEV, and VPA groups, we documented lower global scores in PER than both LEV (<jats:italic>P</jats:italic> < 0.05) and VPA (<jats:italic>P</jats:italic> < 0.05) groups. Moreover, patients under PER treatment showed lower scores than LEV and VPA (<jats:italic>P</jats:italic> < 0.05) in I‐EPI items measuring the gentle personality, anxiety of having epileptic seizures in front of others, and irritability in thinking that they can have an epileptic seizure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This retrospective study described a stable and possibly lower degree of irritability in patients starting PER than LEV and VPA treatments, although we documented the comparable effectiveness of PER, LEV, and VPA as first add‐on treatments in patients affected by uncontrolled epileptic seizures. However, the small sample of patients included in this study and the absence of I‐EPI scores obtained at baseline visits in LEV and VPA groups require further investigations to confirm this preliminary evidence.</jats:p></jats:sec> Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid CNS Neuroscience & Therapeutics |
| doi_str_mv |
10.1111/cns.13098 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Biologie Medizin Psychologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jbnMuMTMwOTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jbnMuMTMwOTg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
1755-5949 1755-5930 |
| issn_str_mv |
1755-5949 1755-5930 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
liguori2019preliminaryevidenceaboutirritabilityinpatientswithepilepsytreatedbyperampanelasfirstaddontherapycomparedtolevetiracetamandvalproicacid |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
CNS Neuroscience & Therapeutics |
| source_id |
49 |
| title |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_unstemmed |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_full |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_fullStr |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_full_unstemmed |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_short |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_sort |
preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| topic |
Pharmacology (medical) Physiology (medical) Psychiatry and Mental health Pharmacology |
| url |
http://dx.doi.org/10.1111/cns.13098 |
| publishDate |
2019 |
| physical |
632-637 |
| description |
<jats:title>Summary</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiatric manifestation in patients affected by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores obtained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order to measure irritability as a consequence of these treatments.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected data from 17 patients treated by PER, 16 patients treated by LEV, and 16 patients under VPA treatment followed for 12 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We did not document significant changes of I‐EPI questionnaire between baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI among PER, LEV, and VPA groups, we documented lower global scores in PER than both LEV (<jats:italic>P</jats:italic> < 0.05) and VPA (<jats:italic>P</jats:italic> < 0.05) groups. Moreover, patients under PER treatment showed lower scores than LEV and VPA (<jats:italic>P</jats:italic> < 0.05) in I‐EPI items measuring the gentle personality, anxiety of having epileptic seizures in front of others, and irritability in thinking that they can have an epileptic seizure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This retrospective study described a stable and possibly lower degree of irritability in patients starting PER than LEV and VPA treatments, although we documented the comparable effectiveness of PER, LEV, and VPA as first add‐on treatments in patients affected by uncontrolled epileptic seizures. However, the small sample of patients included in this study and the absence of I‐EPI scores obtained at baseline visits in LEV and VPA groups require further investigations to confirm this preliminary evidence.</jats:p></jats:sec> |
| container_issue |
5 |
| container_start_page |
632 |
| container_title |
CNS Neuroscience & Therapeutics |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792333579423842314 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:15:00.984Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Preliminary+evidence+about+irritability+in+patients+with+epilepsy+treated+by+perampanel+as+first+add%E2%80%90on+therapy+compared+to+levetiracetam+and+valproic+acid&rft.date=2019-05-01&genre=article&issn=1755-5949&volume=25&issue=5&spage=632&epage=637&pages=632-637&jtitle=CNS+Neuroscience+%26+Therapeutics&atitle=Preliminary+evidence+about+irritability+in+patients+with+epilepsy+treated+by+perampanel+as+first+add%E2%80%90on+therapy+compared+to+levetiracetam+and+valproic+acid&aulast=Placidi&aufirst=Fabio&rft_id=info%3Adoi%2F10.1111%2Fcns.13098&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792333579423842314 |
| author | Liguori, Claudio, Turner, Katherine, Izzi, Francesca, Assogna, Martina, Canevini, Maria P., Mercuri, Nicola B., Placidi, Fabio |
| author_facet | Liguori, Claudio, Turner, Katherine, Izzi, Francesca, Assogna, Martina, Canevini, Maria P., Mercuri, Nicola B., Placidi, Fabio, Liguori, Claudio, Turner, Katherine, Izzi, Francesca, Assogna, Martina, Canevini, Maria P., Mercuri, Nicola B., Placidi, Fabio |
| author_sort | liguori, claudio |
| container_issue | 5 |
| container_start_page | 632 |
| container_title | CNS Neuroscience & Therapeutics |
| container_volume | 25 |
| description | <jats:title>Summary</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiatric manifestation in patients affected by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores obtained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order to measure irritability as a consequence of these treatments.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected data from 17 patients treated by PER, 16 patients treated by LEV, and 16 patients under VPA treatment followed for 12 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We did not document significant changes of I‐EPI questionnaire between baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI among PER, LEV, and VPA groups, we documented lower global scores in PER than both LEV (<jats:italic>P</jats:italic> < 0.05) and VPA (<jats:italic>P</jats:italic> < 0.05) groups. Moreover, patients under PER treatment showed lower scores than LEV and VPA (<jats:italic>P</jats:italic> < 0.05) in I‐EPI items measuring the gentle personality, anxiety of having epileptic seizures in front of others, and irritability in thinking that they can have an epileptic seizure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This retrospective study described a stable and possibly lower degree of irritability in patients starting PER than LEV and VPA treatments, although we documented the comparable effectiveness of PER, LEV, and VPA as first add‐on treatments in patients affected by uncontrolled epileptic seizures. However, the small sample of patients included in this study and the absence of I‐EPI scores obtained at baseline visits in LEV and VPA groups require further investigations to confirm this preliminary evidence.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/cns.13098 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Biologie, Medizin, Psychologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9jbnMuMTMwOTg |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1755-5949, 1755-5930 |
| issn_str_mv | 1755-5949, 1755-5930 |
| language | English |
| last_indexed | 2024-03-01T14:15:00.984Z |
| match_str | liguori2019preliminaryevidenceaboutirritabilityinpatientswithepilepsytreatedbyperampanelasfirstaddontherapycomparedtolevetiracetamandvalproicacid |
| mega_collection | Wiley (CrossRef) |
| physical | 632-637 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | CNS Neuroscience & Therapeutics |
| source_id | 49 |
| spelling | Liguori, Claudio Turner, Katherine Izzi, Francesca Assogna, Martina Canevini, Maria P. Mercuri, Nicola B. Placidi, Fabio 1755-5930 1755-5949 Wiley Pharmacology (medical) Physiology (medical) Psychiatry and Mental health Pharmacology http://dx.doi.org/10.1111/cns.13098 <jats:title>Summary</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiatric manifestation in patients affected by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores obtained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order to measure irritability as a consequence of these treatments.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected data from 17 patients treated by PER, 16 patients treated by LEV, and 16 patients under VPA treatment followed for 12 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We did not document significant changes of I‐EPI questionnaire between baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI among PER, LEV, and VPA groups, we documented lower global scores in PER than both LEV (<jats:italic>P</jats:italic> < 0.05) and VPA (<jats:italic>P</jats:italic> < 0.05) groups. Moreover, patients under PER treatment showed lower scores than LEV and VPA (<jats:italic>P</jats:italic> < 0.05) in I‐EPI items measuring the gentle personality, anxiety of having epileptic seizures in front of others, and irritability in thinking that they can have an epileptic seizure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This retrospective study described a stable and possibly lower degree of irritability in patients starting PER than LEV and VPA treatments, although we documented the comparable effectiveness of PER, LEV, and VPA as first add‐on treatments in patients affected by uncontrolled epileptic seizures. However, the small sample of patients included in this study and the absence of I‐EPI scores obtained at baseline visits in LEV and VPA groups require further investigations to confirm this preliminary evidence.</jats:p></jats:sec> Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid CNS Neuroscience & Therapeutics |
| spellingShingle | Liguori, Claudio, Turner, Katherine, Izzi, Francesca, Assogna, Martina, Canevini, Maria P., Mercuri, Nicola B., Placidi, Fabio, CNS Neuroscience & Therapeutics, Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid, Pharmacology (medical), Physiology (medical), Psychiatry and Mental health, Pharmacology |
| title | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_full | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_fullStr | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_full_unstemmed | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_short | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_sort | preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| title_unstemmed | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid |
| topic | Pharmacology (medical), Physiology (medical), Psychiatry and Mental health, Pharmacology |
| url | http://dx.doi.org/10.1111/cns.13098 |